Bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Outcomes-based contract offerings available to both commercial payers and Medicaid


LYFGENIA will be available through bluebird’s established national network of Qualified Treatment Centers...

Related Keywords

United States ,Louisiana ,Tom Klima ,Shantel Herbert Magee ,Instagram ,Exchange Commission ,Treatment Centers Qtcs ,Treatment Centers ,Treatment Centers Are Ready For Patients ,Nasdaq ,Youtube ,Linkedin ,Qualified Treatment Centers ,Care Anticipated ,Enable Timely Access ,Chief Medical Director ,Treatment Centers Are Ready ,Assist Patients ,Families Throughout ,Patient Navigators ,Safety Information ,Boxed Warning ,Marketing Long Term Follow Up Study ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,